Company profile
Evolus, Inc.
NASDAQ: EOLS · Healthcare · Drug Manufacturers - Specialty & Generic
#250 of 1,422 Healthcare companies by revenue57th-percentile growth
EA Score
59CFH 51DQ 65GM 67SS 66
v0.1 · 65/100 weight · provisional
↑ filing timeliness, workforce scale · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$301.8M
Rev growth YoY (TTM)
+9.6%
Net income (FY)
-$51.6M
Employees
350
as of 2026-08-12
Market cap
$549.2M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$297.2M$297.2M2025
Net income-$51.6M-$51.6M2025
Operating income-$32.7M-$32.7M2025
Total assets$225.9M$225.9M2025
Liabilities$249.0M$249.0M2025
Equity-$23.1M-$23.1M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product99%
Service1%
By geography
Not disclosed.
The read
What is Evolus, Inc.’s revenue?
Evolus, Inc. booked $297.2M in FY2025 revenue, growing 12% year over year — about the middle of the pack among Healthcare companies we track, at a -17.4% net margin.
Peers · Healthcare
BillionToOne, Inc.53DHealthStream, Inc.82B+The Beauty Health Company57CIronwood Pharmaceuticals, Inc.79B+Inogen, Inc.71BRigel Pharmaceuticals, Inc.81B+Neighbors
Orange →Key facts
CEODavid Moatazedi
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersNewport Beach, CA
ExchangeNASDAQ: EOLS
Employees350
IPO date2018-02-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.